After years of following this counter, I come out with one...

After years of following this counter, I come out with one conclusion: this stock is very much stick to its fundamental value. Very few buyers even know about this counter.

The only way to push share price and sustain it in higher level, is to show some real earning distributed back to investors. But we still have clinical trials and more marketing to do...

Any of our midkine antibodies enter or plan to enter stage 1 (2?) how costly will that be?